Biosimilar Market Badania

---

Biosimilar Market Research: How Leading Manufacturers Capture Share in a Maturing Category

Biosimilar market research has shifted from launch readiness to long-term franchise defense. The originator cliff is no longer the prize. The contested ground is formulary persistence, payer mix, and provider switching economics three to five years after entry.

Reference products like Humira, Remicade, Avastin, Herceptin, Rituxan, and Lantus have all faced biosimilar competition across the United States and EU5. The patterns are now visible. Share gains correlate less with price and more with channel design, contracting sophistication, and the buying committee inside integrated delivery networks. Senior commercial leaders evaluating a biosimilar portfolio need intelligence that reflects this reality, not models built on the small-molecule generic playbook.

Why Biosimilar Market Research Requires a Different Lens

Biosimilars are not generics. The interchangeability designation in the United States, the prescriber-led substitution norms across most EU markets, and the buy-and-bill economics of Medicare Part B create a commercial system unlike oral solids. ASP plus six percent reimbursement rewards higher-priced products at the provider level, which inverts the price-leadership instinct from generics.

The successful entrants understood this early. Pfizer’s Inflectra, Sandoz’s Zarxio, Amgen’s Mvasi, and Celltrion’s Truxima each built different go-to-market models tied to site of care, GPO contracting, and 340B exposure. The common thread was disciplined evidence on what the buying committee actually weighed: rebate flow, white-bagging policy, EHR ordering defaults, and the medical director’s view of switch studies.

According to SIS International Research, biosimilar share trajectories diverge most sharply not at launch but in the 18-to-30-month window when payer formulary cycles align with renewed GPO contracts. Manufacturers that resourced provider-level account management during this window captured durable share. Those that relied on national rebate strategy alone saw share plateau below modeled forecasts.

The Buying Committee Is the Unit of Analysis

Volume in oncology, immunology, and supportive care biosimilars is concentrated in a small number of decision-makers. The pharmacy and therapeutics committee, the value analysis committee at the IDN level, the GPO clinical pharmacy lead, and the practice administrator at community oncology networks like The US Oncology Network and American Oncology Network move the majority of units.

Each member weighs different evidence. The P&T pharmacist wants immunogenicity data and switch study quality. The CFO of the practice wants the spread between ASP and acquisition cost. The medical director wants nursing workflow and infusion chair turnover. Generic biosimilar messaging that treats these as one audience underperforms.

SIS International’s B2B expert interview programs across oncology and rheumatology buying committees consistently surface the same finding. The decision is sequential, not simultaneous. Clinical acceptance gates economic conversation. Manufacturers that sequence their evidence package to match this order shorten the formulary review by one to two cycles.

Pricing Architecture Beats Headline Discount

The list price gap between originator and biosimilar matters less than the net realized economics across the channel. WAC discount, ASP trajectory, GPO admin fee, 340B ceiling price interaction, and patient out-of-pocket through Part B coinsurance all compound. A biosimilar launched at 15 percent below WAC can deliver a worse provider economic than one launched at 30 percent below WAC, depending on rebate timing and ASP reset cadence.

Trastuzumab and rituximab biosimilar dynamics illustrate the point. Multiple entrants compressed ASP within four quarters, but providers favored the products with predictable spread and clean contracting terms. The leaders did not always have the lowest list price.

Source: SIS International Research

Competitive Intelligence Beyond the Molecule

The originator response is now predictable in form but variable in execution. AbbVie’s defense of Humira, Roche’s response on Herceptin and Avastin, and Janssen’s contracting around Remicade each offered a template. Authorized biosimilars, second-generation formulations, citrate-free or high-concentration versions, and aggressive rebate walls reshape the addressable share.

Effective biosimilar market research tracks the originator’s contracting posture quarter over quarter. Rebate trap structures inside PBM formularies, exclusion list movements at CVS Caremark, Express Scripts, and OptumRx, and the timing of patent settlement disclosures all change the realistic share ceiling. Manufacturers that model a static originator lose forecast credibility within two cycles.

SIS International’s competitive intelligence work in immunology and oncology biosimilars indicates that the originator’s defensive contracting often peaks 9 to 12 months after the second biosimilar entrant arrives, not the first. Entry sequence matters more than entry timing for late movers planning their commercial investment.

Geographic Variance Is Strategic, Not Operational

Biosimilar uptake in Norway, Denmark, and Germany has been driven by tender systems and regional sickness fund mandates. The United Kingdom’s NHS commissioning approach produced switch rates above 90 percent for several molecules within 18 months. The United States moves through provider economics. Japan moves through Chuikyo pricing decisions and prescriber inertia. Brazil and Mexico move through public tender wins tied to local manufacturing partnerships.

A global biosimilar strategy built on a single commercial model leaves share on the table in three of those five systems. The market entry assessment work that resolves this question requires in-country expert interviews, payer archetype mapping, and tender history analysis specific to each molecule class.

The SIS Biosimilar Intelligence Framework

Effective biosimilar market research integrates four evidence streams that most internal commercial teams run separately:

• Buying committee mapping. Named decision-makers at the top 50 IDNs, top 20 community oncology networks, and top 10 GPOs, with weighted influence by molecule class.
• Channel economics modeling. ASP trajectory simulation under multiple entrant scenarios, with 340B and Part B interaction effects.
• Originator response tracking. Quarterly competitive intelligence on rebate posture, formulary exclusion movements, and second-generation pipeline.
• Country-specific access pathway. Tender calendar, HTA submission requirements, and switching policy by market.

SIS International has applied this framework for biopharmaceutical manufacturers entering oncology, immunology, and supportive care biosimilar categories across North America, Europe, and Asia-Pacific. The work pairs B2B expert interviews with payer and provider stakeholders, competitive intelligence on originator contracting, and forecast models that reflect the actual economics of buy-and-bill rather than the abstractions of list-price modeling.

What Distinguishes the Leaders

The biosimilar manufacturers gaining durable share treat the category as a contracting business with clinical evidence support, not a clinical category with pricing support. They invest in account-level intelligence rather than national average data. They model the originator’s defensive moves as a function of entrant count and sequence rather than as a fixed competitor. They sequence their evidence to match how buying committees actually decide.

The opportunity in biosimilar market research is no longer about proving the category. The category is proven. The opportunity is precision. Manufacturers that resource intelligence at the buying committee level, the contract level, and the country-specific access level will continue to outperform peers running national models.

Key Questions

Q: What is biosimilar market research?
A: Biosimilar market research is the structured intelligence work that informs launch sequencing, pricing architecture, payer and provider contracting, and originator response tracking for biosimilar molecules. It combines buying committee mapping, channel economics modeling, and competitive intelligence specific to buy-and-bill or tender-based commercial systems.

Q: How is biosimilar research different from generic drug research?
A: Biosimilars operate under prescriber-led substitution rather than pharmacist-level substitution, which makes the buying committee and channel economics central. Generic models built on AWP discounting and pharmacy-level substitution misrepresent the dynamics of Medicare Part B reimbursement and IDN formulary decisions.

Q: When does biosimilar share peak after launch?
A: Share trajectories typically diverge in the 18-to-30-month window after launch, when payer formulary cycles align with renewed GPO contracts. This is the period that determines durable share, not the first six months of uptake.

Q: Which biosimilar markets behave most differently?
A: Norway, Denmark, Germany, and the UK move through tender systems and centralized switch policies. The United States moves through provider economics under buy-and-bill. Japan and Brazil move through national pricing and public tender mechanisms. A single global commercial model underperforms across this spread.

Q: What does originator defense look like in mature biosimilar categories?
A: Authorized biosimilars, second-generation formulations, citrate-free or high-concentration versions, and rebate trap contracting through PBM formularies. The defensive posture typically peaks after the second biosimilar entrant, not the first.

O firmie SIS International

SIS Międzynarodowy oferuje badania ilościowe, jakościowe i strategiczne. Dostarczamy dane, narzędzia, strategie, raporty i spostrzeżenia do podejmowania decyzji. Prowadzimy również wywiady, ankiety, grupy fokusowe i inne metody i podejścia do badań rynku. Skontaktuj się z nami dla Twojego kolejnego projektu badania rynku.